GLPG:US
29,20 $
1,53 %
Galapagos NVActivité des initiés
Dernière mise à jour : 2 juin 2025, 18 H 25 (HE)
Profil
DESCRIPTION DE LA SOCIÉTÉ
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.